Copyright
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 14, 2019; 25(6): 719-728
Published online Feb 14, 2019. doi: 10.3748/wjg.v25.i6.719
Published online Feb 14, 2019. doi: 10.3748/wjg.v25.i6.719
Serum hepatitis B virus RNA is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis B patients
Hao Luo, Ning Tan, Qian Kang, Hong-Li Xi, Min Yu, Xiao-Yuan Xu, Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China
Xia-Xia Zhang, Department of Gastroenterology, Capital Medical University Beijing Tiantan Hospital, Beijing 100070, China
Li-Hua Cao, Department of Infectious Diseases, the Third Hospital of Qinhuangdao, Qinhuangdao 066000, Hebei Province, China
Author contributions: Luo H and Zhang XX equally designed the research; Luo H performed the research, acquired and analyzed the data, and wrote the article; Cao LH and Xi HL analyzed the data; Tan N, Kang Q, and Yu M acquired the data; Xu XY edited, reviewed, and approved the final article.
Supported by the 13th Five-Year Plan , No. 2018ZX09206005-002 .
Institutional review board statement: The study protocol conformed to the ethical guidelines of the Declaration of Helsinki and was approved by the Ethic Committee of Shanghai Jing An Central Hospital (Approval No. 090f51e6809a26e1 v1.0).
Informed consent statement: Patients who were enrolled in the work provided informed consent.
Conflict-of-interest statement: There are no conflicts of interest to report.
Data sharing statement: No additional data are available.
STROBE statement: The guidelines of the STROBE Statement have been adopted.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Xiao-Yuan Xu, MD, Professor, Department of Infectious Diseases, Peking University First Hospital, 8 Xishiku Street, Beijing 100034, China. xiaoyuanxu6@163.com
Telephone: +86-10-83575787 Fax: +86-10-83575787
Received: November 5, 2018
Peer-review started: November 5, 2018
First decision: December 28, 2018
Revised: January 11, 2019
Accepted: January 18, 2019
Article in press: January 18, 2019
Published online: February 14, 2019
Processing time: 101 Days and 21.6 Hours
Peer-review started: November 5, 2018
First decision: December 28, 2018
Revised: January 11, 2019
Accepted: January 18, 2019
Article in press: January 18, 2019
Published online: February 14, 2019
Processing time: 101 Days and 21.6 Hours
Core Tip
Core tip: HBeAg seroconversion was more likely to be achieved for chronic hepatitis B patients with hepatitis B virus (HBV) RNA levels below 4.12 log10 copies/mL before treatment. In the partial virological response group, serum HBV RNA showed an increasing trend.